Cell Culture Technology– category –
-
Democratizing Immunotherapy: Tec de Monterrey Pioneers Cost-Effective NK Cell Production Using Autologous Plasma
Facebook (Tec de Monterrey) Mexico Overview A research team at Tec de Monterrey's Toluca campus in Mexico has developed an innovative method to optimize natural killer (NK) cell cultures, utilizing readily available autologous human plas... -
Next-Gen CAR-T Manufacturing Reduces Production Time to 1-2 Days, Explores Decentralized Models for Potent Cells
Bioprocess International USA Overview An article in Bioprocess International highlights advancements in next-generation CAR-T cell therapy manufacturing, which are set to reduce production times to as little as one or two days, yielding ... -
Leman Biotech Raises RMB 200M (USD 29M) Series A+ to Advance Ultra-Low-Dose Metabolically Armored CAR-T to Phase I Trials and Automated Manufacturing Scale-Up
Insight, China's Pharmaceutical Industry China Overview Leman Biotech has secured RMB 200 million (approximately USD 29 million) in Series A+ funding to advance Phase I trials of its ultra-low-dose metabolically armored CAR-T cell therap... -
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
Cell-Easy Expands Toulouse R&D to Scale Allogeneic NK Cell Therapy (10x Cost Reduction), Optimize G-Rex® CAR-T, and Advance iPSC-Derived Beta Cells
Cell-Easy (press release) France Overview Cell-Easy, a CDMO, announced the expansion of its Toulouse R&D facilities to accelerate three next-generation cell therapy manufacturing programs. The company aims for a ten-fold cost reducti... -
Lineage Cell Therapeutics Secures US Patent for AlloSCOPE™ 5D Platform, Advancing Scalable Allogeneic iPSC Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics has been granted a U.S. Patent for its proprietary AlloSCOPE™ 5D manufacturing platform, designed for high-volume, low-passage, undifferentiated, and genetically stable pluripotent ste... -
CAR-T Cell Therapy Manufacturing Breakthrough: Automated Bioreactors Cut Production Time Below 48 Hours, Reduce Costs by 35%
PMC USA Overview Recent research highlights significant advances in CAR-T cell therapy manufacturing, with automated bioreactors enabling point-of-care biomanufacturing that reduces cell product time to less than 48 hours and cuts costs ... -
AI-Integrated Bioreactors Revolutionize Allogeneic Cell Therapy Manufacturing, Unlocking Scalability and Affordability
sanandres.uep.edu.py Paraguay Overview Allogeneic cell therapy manufacturing is undergoing a significant transformation, driven by the integration of automated, closed-system bioreactors and AI/machine learning for real-time monitoring. ... -
Automated iPSC Manufacturing Achieves Monoclonal Lines in Seven Weeks, Paving Way for Cost-Efficient Clinical Autologous Therapies
bioRxiv Unknown Overview A new study introduces a highly efficient, standardizable, and automatable workflow for generating monoclonal induced pluripotent stem cell (iPSC) lines from human skin biopsies, including comprehensive quality c... -
Cell Culture Technology Weekly Report September 6, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 06, 2026 (PDF) — Download Weekly Report September 06, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe...
